KRAS and pancreatic neoplasm: KRB-456 binds KRAS (ITC and protein NMR data), inhibits the binding of KRAS to RAF1 in vitro (alpha screen and GST-RBD pulldown) as well as in intact cancer cells (co-immunoprecipitation with KRAS and blotting with RAF-1 and GST-RBD pulldown) and inhibits the immediate RAS/RAF downstream effector P-MEK clearly demonstrating that KRB-456 engages its target and suppresses KRAS oncogenic signaling in pancreatic cancer.